Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Genital Herpes Health Center

Font Size

Vaginal Treatment May Prevent Herpes

Topical Use of siRNAs Keeps Mice Herpes-Free; Approach Has Anti-HIV Potential
WebMD Health News
Reviewed by Louise Chang, MD

Jan. 21, 2009 -- Small anti-herpes RNA molecules applied to the vagina protect mice against new herpes simplex virus type 2 (HSV-2) infections for one week.

The preventive treatment uses small interfering RNA (siRNA) molecules. These tiny bits of genetic material are designed to switch off specific genes.

The herpes treatment uses two siRNAs. One keeps vaginal cells from producing a molecule that the herpes virus uses to infect cells. The other siRNA targets a viral gene required for herpes reproduction.

"One of the attractive features of the compound we developed is that it creates in the tissue a state that's resistant to infection, even if applied up to a week before sexual exposure," Harvard researcher Judy Lieberman, PhD, says in a news release. "This aspect has a real practicality to it. If we can reproduce these results in people, this could have a powerful impact on preventing transmission."

HSV-2 is the main cause of genital herpes. It's considered a sexually transmitted infection, although mother-to-infant transmission occurs during the birth process.

Researchers have long believed that herpes and HIV could be prevented by vaginal application of antiviral agents. But such "vaginal microbicides," even if effective, must be safe, non-messy, and long-lasting to be of real use to women.

Lieberman's team came up with an earlier version of their topical siRNA but found that the formulation they used actually encouraged herpes infection. Their current, two-pronged siRNA treatment avoids this problem -- at least in mice.

However, the same target they used in mouse vaginal cells -- a molecule called nectin-1 -- is also found on human vaginal cells. Blocking nectin-1 doesn't seem to harm mice. It may not harm humans, either, as the molecule seems to be needed during development but not during adult life.

That suggests the drug might not be safe during pregnancy. But if it works in sexually active adults, it would still be an enormous benefit to human health. An estimated 536 million people worldwide are infected with HSV-2. And HSV-2 infection makes it easier for a person to get infected with HIV.

Lieberman and colleagues suggest their siRNA approach might also work against HIV.

Their study appears in the Jan. 22 issue of Cell Host & Microbe.

Today on WebMD

STD Overview
BHC Healthy Sex Life
things your guy wish you knew slideshow
Sex Drive Killers 03
Genital Herpes Risks Quiz
Young couple holding hands
Hepatitis Prevent 10
Herpes Vaccine Study
Daughter Development Evaluator
HPV Vaccine Future
STD Facts Quiz
mother and daughter talking

WebMD Special Sections